Close Menu

Books in a Library

Treatment of One Case with Cryoglobulinaemia Secondary to Connective Tissue Disease by Small Doses of Rituximab



Objective: This study aims to observe the clinical efficacy of low-dose rituximab patients with cryoglobulinaemia secondary to connective tissue diseases.

Methods: Rituximab (100 mg) was infused in patients once a week for four weeks, combined with prednisone (20 mg) once a day and reduced regularly. The treatment effect was observed regularly.

Results: Joint pain, fever, rash and fatigue symptoms in patients eased. The serology (globulin, erythrocyte sedimentation rate, C-reactive protein, lactate dehydrogenase and others) parameters returned to normal.

Conclusion: Low-dose rituximab therapy for cryoglobulinaemia secondary to connective tissue diseases was safe and effective and can be used as a treatment option in this condition.

06 Jan, 2015
PDF Attachment: 
e-Published: 04 Apr, 2016
Top of Page